Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on ...
Taysha Gene Therapies Inc. Annual stock financials by MarketWatch. View the latest TSHA financial statements, income statements and financial ratios.
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion ...
DALLAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus ...
With strong 1-year returns and upside potential, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. As of December 17, ...
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting Rett Syndrome. The gene therapy market is projected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results